ARTICLE | Distillery Therapeutics
Neurology
April 25, 2017 4:02 PM UTC
Mouse studies suggest inhibiting ATXN2 expression could help treat spinocerebellar ataxia type 2 (SCA2), and ALS and other TDP-43-associated neurodegenerative diseases. In two transgenic mouse models ...
BCIQ Target Profiles